Tanya led the preclinical rolling review for COVID anti-viral applications resulting in national roll-out, and was product lead for the review of a vast array of development programmes via UK innovative licensing pathways: iLAP and EAMs. In addition, Tanya has working knowledge of the collaborative review of promising oncology treatments alongside Australia (TGA), Canada (Health Canada), UK (MHRA), Singapore (HSA), Switzerland (Swissmedic) and Brazil (ANVISA): ‘Project ORBIS’.This experience follows a background project management of global registrations for big pharma in the generics market and Post-Doctoral developmental biology research [UK (UCL) and US (Columbia)].
-
PhD Molecular Biology, BSc Biotechnology
-
Pre-clinical SME
-
Product life-cycle development